UBS Group
CRL icon

UBS Group’s Charles River Laboratories CRL Stock Holding History

UBS Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-19,600
Closed -$2.85M – 7895
2019
Q1 		$2.85M Buy
+19,600
New +$2.58M ﹤0.01% 2669

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS Group's CRL Position: Q1 2026 in Review

UBS Group increased its Charles River Laboratories (CRL) stake by 88% in Q1 2026, buying an estimated $63.5M and bringing the position to 731,465 shares worth $126M. The position accounts for 0.02% of the portfolio, ranked #879.

UBS Group first reported a position in CRL in Q4 2014 and has held it in 46 quarters since. The position peaked at $360M in Q1 2025. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • UBS Group held 731,465 shares of Charles River Laboratories worth $126M as of Q1 2026.
  • UBS Group bought 342,638 Charles River Laboratories shares in Q1 2026, an estimated $63.5M.
  • Charles River Laboratories made up 0.02% of UBS Group's portfolio in Q1 2026, its #879 holding.
  • UBS Group first reported a position in Charles River Laboratories in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Charles River Laboratories position peaked at $360M in Q1 2025.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.